Lipid metabolism reprogramming in cardiac fibrosis
Trends in Endocrinology & Metabolism · 2024-02 · 35 (2) · 164-175
DOI: 10.1016/j.tem.2023.10.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Endocrinology & Metabolism, 2024-02. Verfasst von Li-Chan Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. Hauptthemen laut MEDLINE: Myocardium, Cardiomyopathies. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 103 Literaturangaben.
Abstract (Originalsprache)
Cardiac fibrosis is a critical pathophysiological process that occurs with diverse types of cardiac injury. Lipids are the most important bioenergy substrates for maintaining optimal heart performance and act as second messengers to transduce signals within cardiac cells. However, lipid metabolism reprogramming is a double-edged sword in the regulation of cardiomyocyte homeostasis and heart function. Moreover, lipids can exert diverse effects on cardiac fibrosis through different signaling pathways. In this review, we provide a brief overview of aberrant cardiac lipid metabolism and recent progress in pharmacological research targeting lipid metabolism alterations in cardiac fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
- Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. Electronic address: yangjingjing@ahmu.edu.cn.
- Institute for Developmental and Regenerative Cardiovascular Medicine, MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092,…
- Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China; Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Anhui Me…
Zitieren
APA
Lin, L. C., Liu, Z. Y., Yang, J. J., Zhao, J. Y., & Tao, H. (2024). Lipid metabolism reprogramming in cardiac fibrosis. Trends in Endocrinology & Metabolism, 35(2), 164-175. https://doi.org/10.1016/j.tem.2023.10.004
Vancouver
Lin LC, Liu ZY, Yang JJ, Zhao JY, Tao H. Lipid metabolism reprogramming in cardiac fibrosis. Trends in Endocrinology & Metabolism. 2024;35(2):164-175. doi:10.1016/j.tem.2023.10.004
BibTeX
@article{Lin2024,
author = {Lin, Li-Chan and Liu, Zhi-Yan and Yang, Jing-Jing and Zhao, Jian-Yuan and Tao, Hui},
title = {Lipid metabolism reprogramming in cardiac fibrosis},
journal = {Trends in Endocrinology & Metabolism},
year = {2024},
volume = {35},
number = {2},
pages = {164--175},
doi = {10.1016/j.tem.2023.10.004}
}
EUVIMED